These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 29995374)
1. [Novel Research Progress of the Recombinant Vaccine for MERS-CoV]. Hu H; Shen Y Bing Du Xue Bao; 2016 Jul; 32(4):495-500. PubMed ID: 29995374 [TBL] [Abstract][Full Text] [Related]
2. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228 [TBL] [Abstract][Full Text] [Related]
4. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model. Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758 [TBL] [Abstract][Full Text] [Related]
5. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078 [TBL] [Abstract][Full Text] [Related]
6. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice. Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656 [TBL] [Abstract][Full Text] [Related]
7. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice. Li E; Yan F; Huang P; Chi H; Xu S; Li G; Liu C; Feng N; Wang H; Zhao Y; Yang S; Xia X Viruses; 2020 Jan; 12(1):. PubMed ID: 31968702 [TBL] [Abstract][Full Text] [Related]
10. [Current Status of Middle East Respiratory Syndrome Vaccines]. Fan Y; Jiang Z; Li P; Den Y; Huang J; Zhu L; Xu Z Bing Du Xue Bao; 2016 Nov; 32(6):825-9. PubMed ID: 30004658 [TBL] [Abstract][Full Text] [Related]
11. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632 [TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain-based subunit vaccines against MERS-CoV. Zhang N; Tang J; Lu L; Jiang S; Du L Virus Res; 2015 Apr; 202():151-9. PubMed ID: 25445336 [TBL] [Abstract][Full Text] [Related]
13. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. Rodon J; Okba NMA; Te N; van Dieren B; Bosch BJ; Bensaid A; Segalés J; Haagmans BL; Vergara-Alert J Emerg Microbes Infect; 2019; 8(1):1593-1603. PubMed ID: 31711379 [TBL] [Abstract][Full Text] [Related]
14. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232 [TBL] [Abstract][Full Text] [Related]
15. [Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice]. Lan J; Lu S; Deng Y; Wen B; Chen H; Wang W; Tan W Bing Du Xue Bao; 2016 Jan; 32(1):77-81. PubMed ID: 27295887 [TBL] [Abstract][Full Text] [Related]
16. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. Wirblich C; Coleman CM; Kurup D; Abraham TS; Bernbaum JG; Jahrling PB; Hensley LE; Johnson RF; Frieman MB; Schnell MJ J Virol; 2017 Jan; 91(2):. PubMed ID: 27807241 [TBL] [Abstract][Full Text] [Related]
17. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568 [TBL] [Abstract][Full Text] [Related]
19. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Choi J; Kim MG; Oh YK; Kim YB Expert Opin Ther Pat; 2017 Jun; 27(6):721-731. PubMed ID: 28121202 [TBL] [Abstract][Full Text] [Related]
20. Prospects for a MERS-CoV spike vaccine. Zhou Y; Jiang S; Du L Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]